公开(公告)号：WO2019157224A1

公开(公告)日：2019-08-15

申请号：PCT/US2019/017116

申请日：2019-02-07

申请人： REGENERON PHARMACEUTICALS, INC.

发明人： BAIK, Andrew ,  CYGNAR, Katherine ,  PRAGGASTIS, Maria

IPC分类号： A61K47/68 ,  A61K38/47 ,  A61K39/395 ,  A61K48/00 ,  C12N9/24 ,  A61P3/00 ,  A61P43/00

CPC分类号： A61P43/00 ,  A01K2207/15 ,  A01K2217/072 ,  A01K2217/075 ,  A01K2217/15 ,  A01K2227/105 ,  A01K2267/0306 ,  A61K38/47 ,  A61K47/6815 ,  A61K47/6849 ,  A61K47/6879 ,  A61K47/6881 ,  A61K47/6901 ,  A61K48/005 ,  A61K2039/505 ,  A61P3/00 ,  C07K16/2839 ,  C07K16/2896 ,  C07K2317/622 ,  C07K2319/33 ,  C12N9/2408 ,  C12N2750/14143 ,  C12Y302/0102

摘要： Compositions and methods for delivering a therapeutic protein to the central nervous system (CNS), in order to treat diseases and disorders that impair the CNS, such as treating lysosomal storage diseases are disclosed. Therapeutic proteins delivered via a therapeutically effective amount of a nucleotide composition encoding the therapeutic protein conjugated to a cell surface receptor-binding protein that crosses the blood brain barrier (BBB) are provided.

公开(公告)号：WO2019118884A1

公开(公告)日：2019-06-20

申请号：PCT/US2018/065768

申请日：2018-12-14

申请人： SILVERBACK THERAPEUTICS, INC.

发明人： THOMPSON, Peter Armstrong ,  ODEGARD, Valerie ,  DUBOSE, Robert Finley ,  SMITH, Sean Wesley ,  COBURN, Craig Alan

IPC分类号： C07K16/08 ,  C07K16/10 ,  C07K16/28 ,  A61K47/68 ,  C07D223/32 ,  C07D471/00 ,  C07F5/02

CPC分类号： C07K16/28 ,  A61K47/6803 ,  A61K47/6807 ,  A61K47/6839 ,  A61K47/6841 ,  A61K47/6849 ,  A61K47/6889 ,  A61K2039/505 ,  A61K2039/58 ,  A61K2039/627 ,  A61P31/12 ,  A61P31/20 ,  C07D215/38 ,  C07D223/16 ,  C07D401/12 ,  C07D401/14 ,  C07D471/04 ,  C07K16/082 ,  C07K16/109 ,  C07K16/2851 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/569 ,  C07K2317/90 ,  C07K2317/92

摘要： Various compositions are disclosed for the treatment of viral infections. The compositions comprise antibody constructs directed to the liver, attached to myeloid cell agonists, specifically TLR7 and TLR8 agonists, via a linker. Additionally provided are the methods of preparation and use of the conjugates. This includes methods for treating viral infections, such as viral liver diseases.

公开(公告)号：WO2019092550A1

公开(公告)日：2019-05-16

申请号：PCT/IB2018/058476

申请日：2018-10-30

申请人： POLITECNICO DI TORINO

发明人： CAUDA, Valentina Alice ,  CANAVESE, Giancarlo ,  LIMONGI, Tania ,  GARINO, Nadia ,  LAURENTI, Marco ,  RACCA, Luisa ,  ANCONA, Andrea ,  CANTA, Marta ,  DUMONTEL, Bianca

IPC分类号： A61K47/68 ,  A61K47/69

CPC分类号： A61K47/6923 ,  A61K47/6849 ,  A61K47/6901 ,  A61K47/6929 ,  A61K49/0058 ,  A61K49/0067 ,  A61K49/0097 ,  A61P35/00

摘要： Nanoassembly (1) for inducing apoptosis in cancer cells comprising: a core (2) comprising at least a nanoparticle of a nano structured and semiconductor metal oxide, said nanoparticle being monocrystalline or polycrystalline; a shell (3) formed by a double phospholipid layer and proteins derived from an extracellular biovesicole chosen between an exosome, an ectosome, a connectosome, an oncosome and an apoptotic body, and an oncosome, said core (2) being enclosed inside said shell (3); and a plurality of targeting molecules (4, 4', 4") of said cancer cells, preferably monoclonal antibodies (4, 4', 4"), said molecules (4, 4', 4") being anchored to the external surface of said biovesicole.

公开(公告)号：WO2019055955A1

公开(公告)日：2019-03-21

申请号：PCT/US2018/051418

申请日：2018-09-18

申请人： THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES

发明人： PASTAN, Ira H. ,  WEI, Junxia ,  ONDA, Masanori ,  BERA, Tapan ,  HO, Mitchell

IPC分类号： C07K16/28 ,  C07K16/30 ,  C07K14/21 ,  A61K47/68 ,  C07K19/00 ,  C12N15/62 ,  A61P35/00

CPC分类号： C07K16/30 ,  A61K47/6829 ,  A61K47/6849 ,  A61K47/6889 ,  C07K14/21 ,  C07K16/2803 ,  C07K16/2866 ,  C07K16/2878 ,  C07K2317/31 ,  C07K2317/569 ,  C07K2317/624 ,  C07K2317/73 ,  C07K2317/94 ,  C07K2319/32 ,  C07K2319/50 ,  C07K2319/55 ,  C07K2319/70

摘要： Disclosed is a molecule comprising: (a) a first domain, which comprises a targeting moiety; (b) a second domain, which comprises an albumin binding domain (ABD), (c) a third domain, which comprises a furin cleavage sequence ("FCS"), which FCS is cleavable by furin; and (d) a fourth domain, which comprises an optionally substituted Domain III from Pseudomonas exotoxin A ("PE"). Related nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, methods of producing the molecule, methods of treating or preventing cancer in a mammal, and methods of inhibiting the growth of a target cell are also disclosed.

公开(公告)号：WO2018187642A1

公开(公告)日：2018-10-11

申请号：PCT/US2018/026381

申请日：2018-04-06

申请人： ABBVIE INC.

发明人： REILLY, Edward B. ,  ANDERSON, Mark G.

IPC分类号： A61K47/68 ,  A61P35/00

CPC分类号： C07K16/2866 ,  A61K47/6803 ,  A61K47/6849 ,  A61K47/6889 ,  A61P35/00 ,  C07K2317/24 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/52

摘要： Provided are antibody drug conjugates that bind PRLR, in particular human PRLR, their methods of making, and uses thereof.

公开(公告)号：WO2018183613A1

公开(公告)日：2018-10-04

申请号：PCT/US2018/025044

申请日：2018-03-29

申请人： THE CHILDREN'S MEDICAL CENTER CORPORATION ,  THE GOVERNMENT OF THE UNITED STATES OF AMERICA D. B. A. DEPARTMENT OF HEALTH AND HUMAN SERVICES

发明人： ROSSI, Derrick J. ,  CZECHOWICZ, Agnieszka D. ,  MURPHY, Philip M. ,  LI, Zhanzhuo

IPC分类号： A61K35/28 ,  A61K47/68 ,  C07K16/28 ,  C07K16/30 ,  C12N5/00

CPC分类号： A61K47/6849 ,  A61K35/28 ,  A61K35/36 ,  A61K38/00 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/6825 ,  A61K2035/124 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/2803 ,  C07K16/2809 ,  C07K16/2815 ,  C07K16/2875 ,  A61K2300/00

摘要： Provided are methods and compositions conditioning a patient for an allogeneic transplantation, wherein the patient's hematopoietic stem cells (HSCs) are depleted with an HSC-depleting composition and the patient is then administered allogeneic cells selected from bone marrow cells, umbilical cord blood cells, hematopoietic stem and progenitor cells (HSPCs), peripheral blood CD34+cells, and peripheral blood CD34+ and CD90+ cells; optionally the patient is also administered a medicament selected from the group consisting of a T-cell depleting or inhibiting antibody or antibody fragment, NK-cell depleting or inhibiting antibody or antibody fragment, immunosuppressive drug, and any combination thereof. The HSC-depleting composition comprises a compound selected from the group consisting of: an antibody or antibody fragment with specific binding affinity to a protein displayed at the HSC surface, a conjugate comprising an HSC-recognition molecule and a toxin, and any combination thereof.

公开(公告)号：WO2018160538A1

公开(公告)日：2018-09-07

申请号：PCT/US2018/019873

申请日：2018-02-27

申请人： MERSANA THERAPEUTICS, INC. ,  MILLENNIUM PHARMACEUTICALS, INC.

发明人： BODYAK, Natalya D. ,  BERGSTROM, Donald A. ,  HYER, Marc ,  LOWINGER, Timothy B. ,  PROTOPOPOVA, Marina ,  VEIBY, Ole Petter ,  YURKOVETSKIY, Aleksandr V. ,  ZHANG, Qing Xiu

IPC分类号： C07K16/28 ,  C07K16/32 ,  A61K47/64 ,  C12N5/10

CPC分类号： A61K47/6883 ,  A61K39/3955 ,  A61K39/39558 ,  A61K47/60 ,  A61K47/6803 ,  A61K47/6809 ,  A61K47/6817 ,  A61K47/6849 ,  A61K47/6851 ,  A61K47/6855 ,  A61K47/6857 ,  A61K47/6863 ,  A61K47/6869 ,  A61K2039/507 ,  A61K2039/545 ,  A61P35/00 ,  C07K16/2818 ,  C07K16/32 ,  C07K2317/32 ,  C07K2317/56 ,  C07K2317/565 ,  C07K16/30

摘要： Disclose herein are combinations comprising HER2-targeted antibody-drug conjugates and immune checkpoint inhibitors and methods of using such combinations in a variety of therapeutic, diagnostic, and prophylactic indications.

公开(公告)号：WO2018129451A2

公开(公告)日：2018-07-12

申请号：PCT/US2018/012791

申请日：2018-01-08

申请人： MERRIMACK PHARMACEUTICALS, INC.

发明人： DAKE, Tamara ,  FINN, Gregory J. ,  GEDDIE, Melissa ,  HASHAMBHOY-RAMSAY, Yasmin ,  MUDA, Marco ,  SCHOEBERL, Birgit M.

IPC分类号： C07K16/28

CPC分类号： C07K16/2863 ,  A61K47/6849 ,  A61K2039/505 ,  A61K2039/507 ,  A61P35/00 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/52 ,  C07K2317/71 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  G01N33/57492 ,  G01N2333/705

摘要： Anti-FGFR antibodies which bind to particular isoforms of FGFR1-4, therapeutic compositions comprising the anti-FGFR antibodies, and methods of using such antibodies and compositions in the treatment of FGFR-related disorders (e.g., cancer) are disclosed.

公开(公告)号：WO2018069851A2

公开(公告)日：2018-04-19

申请号：PCT/IB2017/056295

申请日：2017-10-11

申请人： SORRENTO THERAPEUTICS, INC. ,  ZHU, Tong ,  CHEN, Gang ,  KHASANOV, Alisher

发明人： ZHU, Tong ,  CHEN, Gang ,  KHASANOV, Alisher

IPC分类号： A61K47/68 ,  C07K19/00

CPC分类号： A61K47/6809 ,  A61K47/6849 ,  A61K2039/505 ,  A61K2039/507 ,  A61P35/00 ,  C07K16/2863 ,  C07K2317/24

摘要： Described are antibody drug conjugates (ADCs) having an IgG antibody (A) that binds to a c-Met target, conjugated through a conjugation component at both Cys sites in the hinge region of the IgG antibody and to disulfide bonds linking heavy and light chains of the IgG class human antibody, to a drug (D). More specifically, the present disclosure relates to the drug component (D) of the ADC.

摘要翻译： 描述了具有IgG抗体（A）的抗体药物缀合物（ADCs），其结合c-Met靶标，通过IgG抗体铰链区域中两个Cys位点处的缀合组分偶联和 连接IgG类人抗体的重链和轻链的二硫键连接到药物（D）上。 更具体地说，本公开涉及ADC的药物组分（D）。

公开(公告)号：WO2017127664A1

公开(公告)日：2017-07-27

申请号：PCT/US2017/014311

申请日：2017-01-20

申请人： THE SCRIPPS RESEARCH INSTITUTE ,  NBE-THERAPEUTICS AG

发明人： RADER, Christoph ,  PENG, Haiyong ,  BEERLI, Roger ,  WALDMEIER, Lorenz ,  GRAWUNDER, Ulf

IPC分类号： C07K16/28 ,  C07K14/725 ,  A61K39/395 ,  A61P35/00

CPC分类号： C07K16/2803 ,  A61K47/6849 ,  A61K47/6889 ,  A61K47/6903 ,  A61K2039/505 ,  C07K14/705 ,  C07K14/7051 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/73 ,  C07K2317/90 ,  C07K2317/92 ,  C07K2319/00 ,  C07K2319/03 ,  C12N9/12 ,  C12Y207/10001

摘要： ROR1 Antibody Compositions and Related Methods The disclosure provides antibodies, antibody drug conjugates, antibody-based fragments or antibody fragments (antigen-binding fragments), as well as antibody drug conjugates (ADCs) and chimeric antigen receptors (CARs), that specifically recognize human ROR1 and related compositions. Also provided in the disclosure are methods of using such antibodies in various diagnostic and therapeutic applications.

摘要翻译： ROR1抗体组合物和相关方法本公开提供抗体，抗体药物缀合物，基于抗体的片段或抗体片段（抗原结合片段）以及抗体药物缀合物（ADC）和嵌合抗原受体 （CAR），其特异性识别人ROR1和相关组合物。 本公开内容还提供了将这些抗体用于各种诊断和治疗应用的方法。